Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Vancomycin use has surged globally for methicillin-resistant Staphylococcus aureus (MRSA) infections.
• Historically, vancomycin has been the primary treatment for serious MRSA infections with rare resistance.
• Emerging evidence suggests declining vancomycin efficacy against S. aureus.

Purpose of the Study:

• To evaluate the clinical relevance of current vancomycin susceptibility definitions for S. aureus.
• To investigate the impact of vancomycin heteroresistance on treatment outcomes in MRSA infections.

Main Methods:

• Analysis of clinical data on vancomycin treatment for MRSA infections.
• Review of microbiological definitions of vancomycin susceptibility.
• Assessment of patient mortality and treatment response in relation to vancomycin efficacy.

Main Results:

• Vancomycin potency is diminishing against S. aureus, including MRSA strains.
• Laboratory-defined susceptible MRSA strains show poor response to vancomycin therapy.
• Increased mortality observed in patients with MRSA infections treated with vancomycin.
• Vancomycin heteroresistance significantly attenuates drug efficacy.

Conclusions:

• Current microbiological definitions of vancomycin susceptibility require re-evaluation for serious MRSA infections.
• Vancomycin heteroresistance poses a significant challenge in managing MRSA bacteremia and pneumonia.
• Clinical outcomes suggest a need for revised susceptibility criteria to ensure effective vancomycin therapy.